Member Info for Soupdragon78

Always makes me smile when there is a tiny and insignificant website update undertaken, but hey its been a year in the making.

One page has had one minor change on the 1st Feb at 12.30pm.

Must have been a quiet lunchtime.

If it is the warrants being forward sold, I don’t know how much time they would have before exercising the warrants. That’s part of the dark arts of the market.

Only Dan would have to notify on the same day.

Jo Holland isn’t a director anymore so only has to declare as a major holder, which I think is after 2 days

31.5m clean sells now.

If it is the warrants thats no bad thing a jiving says, its cash to the bottom line of the company.

Thanks Jiving, looks like 26.5m clean sells. (as in round numbers of 1m or 2.5m)

FX, i understand, its not a straightforward thing and shows the 'one rule for us and one rule for them' approach that the market works to.

I guess it relies on the third party receiving the shares before the share sale is closed out. Usually when you buy or sell, whilst it shows straight away in your account it still takes a few days to clear.

So if the warrant holder says to the third party, 'ok you pay me 0.27p per share for my 35m shares and I'll exercise them (at 0.25p)'

The third party could go to the market on day 1, sell the shares at market price (say 0.29p), the warrant holder then exercises them on day two and transfers the shares straight to the third party, who then has the shares by day 3 when they have to close out their sells.

Purely my guess on how it works, so probably full off holes.

FX, with forward selling the warrant holder will make a deal with a third party (broker) in advance of exercising the warrants.

Its like short selling, the warrant holder agrees to give the shares to the third party, so the third party sells the same amount in advance of receiving the actual shares.

Hmmm... to big for Pi's.

My bet is its forward selling the 35m warrants if they are being exercised shortly.

To directly quote Dan on the additional work to NXP002.

"...with NXP002 we are now in a position where we don't have to do any new work that we haven't yet completed we're simply looking at increasing the sample size of data sets that we have so that we can make those data packages suitable for partners in the data and the statistics."

Think it’s more of a relief rally based on the going concern statement, plus written confirmation of discussions underway.

Looks like it FX, those who wanted to talk solely about NFX don't seem to have anything to say.

I guess that’s a no from trans.

Oh well. As you were folks.

Go for it trans, the floor is yours....

Wonder if slave2trade is going to tell us when it’s NT to sell?

Oooh a March AGM this year... fun!

Easy to buy online for 0.412p

You’ll be gone by 0.5p

More very relevant emerging research on the importance of inflammasomes in treating respiratory diseases. In particular the role of NLRP3 which NFX research specifically targets.

Published 5th Jan 2024.

'The role of inflammasomes in human diseases and their potential as therapeutic targets'

Respiratory disorders

Inflammasomes are implicated in the pathogenesis of several respiratory disorders, including asthma, chronic obstructive pulmonary disease (COPD), pulmonary infection, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). As a result, inflammasomes have become a significant focus for research aimed at developing new diagnostic biomarkers and therapeutic avenues in pulmonary diseases and other respiratory disorders.

Asthma is a chronic inflammatory disease of the airways that affects inflammatory cells and cytokines in the lungs.238 Exposure to industrial products, microbes, or other allergens induces reversible limitations in airflow into and out of the lungs, as well as airway hyper-responsiveness. Persistent airway inflammation causes structural changes in airway tissues, known as airway remodeling, resulting in nonreversible airway obstruction and progressive loss of lung function. There is increasing evidence that NLRP3 inflammasome plays a role in asthma.

The end result of inflammatory pulmonary diseases is fibrosis. The NLRP3 inflammasome mediates pulmonary fibrosis through the IL-1β-IL-1Rs-MyD88-NF-κB signaling pathway.263 Moreover, studies also found that NLRP3 inflammasome could transform lung endothelial cells into epithelial-mesenchymal transition, promoting pulmonary fibrosis. Caspase-1 and IL-1β play vital roles in pulmonary fibrogenesis. Caspases-1enzyme cleavages the pro-IL-1β and allows secretion of IL-1β.264 Elevated IL-1β has a profibrotic effect, and usually occurs in combination with higher expression of IL-1Rs in fibrogenesis.265 A study on mouse primary lung fibroblasts showed that the NLRP3 inflammasome increases IL-1β production, leading to lung fibrosis when induced by bleomycin.266 Collectively, these investigations have helped to clarify the role of inflammasomes in the development of pulmonary fibrosis and may lead to the discovery of new treatment targets for various respiratory disorders.

https://www.nature.com/articles/s41392-023-01687-y

0.407p online quotes to buy on HL.